Darifenacin Hydrobromide Darifenacin HBr CAS 133099-07-7 Assay ≥99.0% API Factory High Quality
Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Darifenacin Hydrobromide
CAS: 133099-07-7
Darifenacin hydrobromide is a selective M3 muscarinic receptor antagonist used to treat urinary incontinence and overactive bladder syndrome.
API High Quality, Commercial Production
| Chemical Name | Darifenacin Hydrobromide |
| Synonyms | Darifenacin HBr; UK-88525; Enablex |
| CAS Number | 133099-07-7 |
| CAT Number | RF-API94 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C28H30N2O2.HBr |
| Molecular Weight | 507.46 |
| Melting Point | 228.0~230.0℃ |
| Solubility | DMSO: Soluble 20mg/ml, Clear |
| Storage Temperature | Store Long-term at -20℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White Crystalline Powder |
| Solubility | Sparingly Soluble in Methanol, Slightly Soluble in Water and Practically Insoluble in Chloroform |
| Identification IR | Spectrum of the sample corresponds to that of reference standard |
| Identification HPLC | The retention time of the major peak of the sample solution corresponds to that of the standard solution |
| Related Substances | |
| Max. Single Impurity | ≤0.50% |
| Total Impurities | ≤1.0% |
| Optical Isomer | ≤0.50% |
| Residual Solvents | |
| Ethyl Acetate | ≤0.50% |
| Ethanol | ≤0.50% |
| Methanol | ≤0.30% |
| Acetone | ≤0.50% |
| 1-Butanol | ≤0.50% |
| Loss on Drying | ≤1.0% (Dry at 105℃ in an electric air blowing dryer till a constant weight) |
| Residue on Ignition | ≤0.10% |
| Heavy Metals | ≤20ppm |
| Assay | ≥99.0% (on dried basis) |
| Shelf Life | 24 Months |
| Test Standard | Enterprise Standard |
| Usage | API, Overactive Bladder |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Darifenacin Hydrobromide, Darifenacin HBr (CAS 133099-07-7), an orally active, once a day selective M3 receptor antagonist, was launched for the treatment of overactive bladder in patients with symptoms of urge urinary incontinence, urgency and frequency. The drug selectively inhibits M3 receptor in the detrusor muscle while sparing the M1 and M2 receptors that are believed to be involved in central nervous system and cardiovascular function respectively. The compound was originally developed by Pfizer and licensed to Novartis and Bayer.
